Dorzolamide increases retinal oxygen tension after branch retinal vein occlusion.
OBJECTIVE
To study the effect of dorzolamide on the preretinal oxygen tension (RPO(2)) in retinal areas affected by experimental branch retinal vein occlusion (BRVO) in pigs.


METHODS
Experimental BRVO was induced by diathermy close to the optic disc. RPO(2) was measured with an oxygen-sensitive electrode 0.5 mm above the BRVO-affected area, which was compared to the retinal areas not affected by BRVO. In one group of five pigs, RPO(2) was measured at baseline, 1 and 3 hours after BRVO, and after intravenous injection of 500 mg dorzolamide. In a second group of five pigs, RPO(2) was measured 1 week after the BRVO, both before and after intravenous injection of 500 mg dorzolamide.


RESULTS
The average baseline RPO(2) was 2.64 +/- 0.09 kPa (mean +/- SD). In the BRVO-affected areas, RPO(2) decreased significantly (by 0.67 +/- 0.29 and 0.94 +/- 0.13 kPa) at 1 hour and 3 hours after BRVO induction. In the non-BRVO areas RPO(2) increased significantly (by 0.51 +/- 0.14 kPa) 1 hour after BRVO induction, but subsequently decreased and reached baseline 3 hours after BRVO induction. One week after BRVO induction, RPO(2) was 0.67 +/- 0.29 kPa lower in affected areas when compared with the non-BRVO areas. In the BRVO-affected areas, dorzolamide increased RPO(2) significantly (by 0.36 +/- 0.21 kPa at 3 to 4 hours and by 0.67 +/- 0.40 kPa) 1 week after BRVO induction.


CONCLUSIONS
Retinal hypoxia induced by experimental BRVO remained significant 1 week after BRVO. Dorzolamide increased retinal oxygen tension in the BRVO-affected areas both at 4 hours and 1 week after experimental BRVO in pigs.
Noergaard
Michael Hove
MH
Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. hovemichael@yahoo.com
Bach-Holm
Daniella
D
Scherfig
Erik
E
Bang
Kurt
K
Jensen
Peter Koch
PK
Kiilgaard
Jens Folke
JF
Stefánsson
Einar
E
la Cour
Morten
M
D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005451:Fluorescein Angiography; D000860:Hypoxia / Q000378:metabolism; D007275:Injections, Intravenous; D017736:Ion-Selective Electrodes; D007511:Ischemia / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism*; D010101:Oxygen Consumption; D010313:Partial Pressure; D012160:Retina / Q000378:metabolism; D012170:Retinal Vein Occlusion / Q000378:metabolism*; D013449:Sulfonamides / Q000008:administration & dosage*; D013552:Swine; D013876:Thiophenes / Q000008:administration & dosage*
D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide; D010100:Oxygen